← board
ANIK
distress 2/10 · well-funded / low risk$15.01-1%today-8% from 52w high
Lead: articular cartilage defects in the knee
Revenue
$30M
Liquidity
$67M
Runway
—
Shares 1y
-8%
Price & events
+59.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
-5.8%
1W
+5.7%
1M
-3.5%
3M
+59.9%
6M
+36.5%
1Y
-46.3%
2Y
-62.5%
5Y
-65.0%
All
Overview
- Market Cap
- $199.72M
- Volume
- 57.20K
- 52 Week Range
- $8.10 – $16.34
- Total Shares
- 13.31M
- Float Shares
- 11.21M
- Short %
- 4.12%
- % Held by Insiders
- 6.42%
- % Held by Institutions
- 94.77%
- RVOL
- 0.78x
- Beta
- 0.23
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2026-07-29Estimated 45%earningsEarningsEarnings releaseyahoo
- November 5, 2025regulatory submissionFiled (NDA/BLA)Hyalofast · Filed third and final module of PMA applicationSEC 8-K
- July 30, 2025readoutPhase 3Hyalofast · Topline results from U.S. pivotal Phase III studySEC 8-K
- 2025-03-07partnershipCompleted sale of Parcus Medical to Medacta for $4.5M cash.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-02-27Barrington ResearchOutperform
- 2026-01-09Barrington ResearchOutperform
- 2025-11-06Barrington ResearchOutperform
- 2025-09-23Barrington ResearchOutperform
- 2025-07-31Barrington ResearchOutperform
- 2025-05-12Barrington ResearchOutperform
Competitors — articular cartilage defects in the knee
- none identified
Recent news
- 2026-07-23Anika Therapeutics (ANIK) Proxy filing Summary - Quartr
- 2026-07-23Anika Therapeutics (ANIK) Proxy filing Summary - Quartr
- 2026-07-23Anika Therapeutics (ANIK) Proxy filing Summary - Quartr
- 2026-07-23Anika Therapeutics (ANIK) AGM 2026 Summary - Quartr
- 2026-07-17BlackRock Portfolio Management (NASDAQ: ANIK) discloses 4.1% Anika Therapeutics ownership - Stock Titan
- 2026-07-17Discipline and Rules-Based Execution in ANIK Response - Stock Traders Daily
- 2026-07-15Anika Therapeutics to issue Q2FY26 results on July 29 - scanx.trade
- 2026-07-15Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026 - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.